FTC Blocks Edwards Lifesciences' $945M Heart Device Deal
The Federal Trade Commission filed suit to block Edwards Lifesciences' proposed $945 million acquisition of JenaValve Technology, alleging the deal would create a monopoly in the market for transcatheter aortic valve replacement devices used to treat aortic regurgitation. The FTC argues that combining the only two companies with ongoing U.S. clinical trials for these life-saving heart devices would stifle innovation and increase costs for patients.